Table 1 Patients’ characteristics.
N = 93 | |
|---|---|
Age (years, median, range) | 54 (20–70) |
Menstruation status | |
Premenopausal | 32 (34.4%) |
Postmenopausal | 60 (64.5%) |
Unknown | 1 (1.1%) |
HR status | |
HR ( +) | 53 (57.0%) |
HR (−) | 37 (39.8%) |
Unknown | 3 (3.2%) |
De novo stage IV | 29 (31.2%) |
No. of prior chemotherapy regimens at metastatic setting* (median, range) | 4 (2–11) |
1–3 | 35 (38.0%) |
> 3 | 57 (62.0%) |
Unknown | 1 (1.1%) |
No. of prior anti-HER2 therapy at metastatic setting** (median, range) | 3 (0–8) |
1–3 | 71 (76.3%) |
> 3 | 22 (23.7%) |
Prior anti-HER2 agents | |
Trastuzumab | 90 (96.8%) |
Pertuzumab | 39 (41.9%) |
Trastuzumab emtansine (T-DM1) | 90 (96.8%) |
Lapatinib | 70 (75.3%) |
Trastuzumab deruxtecan (T-Dxd) | 9 (9.7%) |
